Drugs /

tipifarnib

Back to Drugs List

Overview

Generic Name(s):
tipifarnib
Trade Name(s):
Zarnestra
NCI Definition [1]:
A nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits the enzyme farnesyl protein transferase, an enzyme involved in protein processing (farnesylation) for signal transduction. By inhibiting the farnesylation of proteins, this agent prevents the activation of Ras oncogenes, inhibits cell growth, induces apoptosis, and inhibits angiogenesis. (NCI04)

Clinical Trials

View Clinical Trials for tipifarnib

Tipifarnib has been investigated in 9 clinical trials, of which 5 are open and 4 are closed. Of the trials investigating tipifarnib, 9 are phase 2 (5 open).

HRAS Mutation, HRAS Missense, and ALK Expression are the most frequent biomarker inclusion criteria for tipifarnib clinical trials.

Malignant solid tumor, anaplastic large cell lymphoma, and head and neck squamous cell carcinoma are the most common diseases being investigated in tipifarnib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Tipifarnib
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Tipifarnib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating tipifarnib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
ind 58359, Zarnestra, tipifarnib, 58359, r 115777, (+)-6-[amino(4-chlorophenyl)(1-methyl-1h-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1h)-quinolinone, tipifarnib, r-115777, r115777, 702818, 192185-72-1, (+)-6-[amino(4-chlorophenyl)(1-methyl-1h-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1h)-quinolinone
Drug Categories [2]:
Farnesyl transferase inhibitor
Drug Target(s) [2]:
FNTA, FNTB
NCIT ID [1]:
C1703

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.